« Return to News | Clinical Intelligence

Asubio broadens inclusion criteria for spinal cord injury trial

Thursday, July 11, 2013 10:00 AM

Asubio Pharmaceuticals has expanded enrollment for its ASCENT-ASCI (Asubio Spinal Cord Early Neuro-recovery Treatment for Acute Spinal Cord Injury) trial to include AIS A, B and C injury to the cervical spine. ASCENT-ASCI is a phase II clinical trial evaluating SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

The company is currently working with 45 acute trauma centers throughout the U.S. and Canada and plans to increase to 55 centers. Trauma centers must first sign up to participate in the trial and then brief attending trauma physicians and nurses on how to rapidly identify eligible spinal cord injury patients when they first arrive at their facility. There are also 13 standalone rehabilitation centers participating.

"The recent adoption of a more inclusive Asubio trial protocol will meet the needs of a broader number of spinal cord injuries and enable a more sensitive and accurate determination of therapeutic benefit across a wider range of functional disability," said John Steeves, Ph.D., professor and founding director of ICORD (International Collaboration On Repair Discoveries). 

"It takes a small community to pull off an acute spinal cord injury study, but with a bit of planning, it can be done," explained Laura Wollenweber, a clinical research coordinator at the Medical College of Wisconsin in Milwaukee, who spoke of her experience enrolling patients in the study. "We are hopeful that the broadened enrollment criteria will bring new hope for a wider range of patients."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.